CMX-020 is under clinical development by Cmxtwenty and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CMX-020’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 20 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CMX-020 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CMX-020 is under development for the treatment of osteoarthritis and knee osteoarthritis, lumbosacral radiculopathy, pain and chronic pain. It is an analog of arachidonic acid. The drug candidate is formulated as enteric coated softgelatin capsules and administered through oral and intravenous routes. It targets multiple cannabinoid receptors including CB1, CB2 and TRPV1.
Cmxtwenty focuses on developing lipid compounds for use in non-narcotic pain treatment. The company is headquartered in Milwaukee, Wisconsin, the US
Quick View CMX-020 LOA Data
|Highest Development Stage|